PMID- 22927112
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20161125
IS  - 1573-6776 (Electronic)
IS  - 0141-5492 (Linking)
VI  - 34
IP  - 12
DP  - 2012 Dec
TI  - T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates 
      lipopolysaccharide-induced liver injury in mice.
PG  - 2175-82
LID - 10.1007/s10529-012-1022-4 [doi]
AB  - The effect of T-5224, a selective inhibitor of c-Fos/activator protein (AP)-1, on 
      lipopolysaccharide (LPS) induced liver injury was examined in mice. 
      Administration of LPS (10 mg kg(-1), i.p.) markedly increased serum levels of 
      tumor necrosis factor-alpha (TNFalpha), high mobility group box 1 (HMGB1), alanine 
      aminotransferase/aspartate aminotransferase (ALT/AST), liver tissue levels of 
      macrophage-inflammatory protein-1 alpha (MIP-1alpha) and monocyte chemoattractant 
      protein-1 (MCP-1), as well as hepatic necrosis and inflammation, leading to 67 % 
      lethality. Administration of T-5224 (300 mg kg(-1), p.o.) after intraperitoneal 
      injection of LPS imparted appreciable protection against acute elevations in 
      serum levels of TNFalpha, HMGB1, ALT/AST as well as in liver tissue levels of MIP-1alpha 
      and MCP-1, and reduced the lethality (27 %). These data indicate that T-5224 
      ameliorates liver injury and improves survival through decreasing production of 
      proinflammatory cytokines and chemokines in endotoxemic mice.
FAU - Izuta, Shinichiro
AU  - Izuta S
AD  - Division of Intensive Care Medicine, Kobe University Hospital, Chuo-ku, Kobe, 
      Japan. izuta@med.kobe-u.ac.jp
FAU - Ueki, Masaaki
AU  - Ueki M
FAU - Ueno, Masaki
AU  - Ueno M
FAU - Nishina, Kahoru
AU  - Nishina K
FAU - Shiozawa, Shunichi
AU  - Shiozawa S
FAU - Maekawa, Nobuhiro
AU  - Maekawa N
LA  - eng
PT  - Journal Article
DEP - 20120825
PL  - Netherlands
TA  - Biotechnol Lett
JT  - Biotechnology letters
JID - 8008051
RN  - 0 
      (3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic 
      acid)
RN  - 0 (Benzophenones)
RN  - 0 (Cytokines)
RN  - 0 (Enzymes)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Isoxazoles)
RN  - 0 (Lipopolysaccharides)
SB  - IM
MH  - Animals
MH  - Benzophenones/*administration & dosage/pharmacology
MH  - Chemical and Drug Induced Liver Injury/*prevention & control
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Enzymes/blood
MH  - Gastrointestinal Agents/*administration & dosage/pharmacology
MH  - Hepatitis, Animal/chemically induced/prevention & control
MH  - Isoxazoles/*administration & dosage/pharmacology
MH  - Lipopolysaccharides/*toxicity
MH  - Liver/*drug effects/*pathology
MH  - Mice
MH  - Survival Analysis
EDAT- 2012/08/29 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/08/29 06:00
PHST- 2012/06/05 00:00 [received]
PHST- 2012/07/16 00:00 [accepted]
PHST- 2012/08/29 06:00 [entrez]
PHST- 2012/08/29 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - 10.1007/s10529-012-1022-4 [doi]
PST - ppublish
SO  - Biotechnol Lett. 2012 Dec;34(12):2175-82. doi: 10.1007/s10529-012-1022-4. Epub 
      2012 Aug 25.